用定量预测模型识别基因多态性下CYP介导的药物相互作用风险
该研究用体内机制性静态模型预测CYP介导的药物相互作用,考虑5种CYP和3种多态CYP的5类基因型,计算196种底物与96种抑制剂的AUC比。共识别104个基因敏感性大于3的相互作用,其中高敏感59例、中敏感45例,CYP2D6和CYP2C19慢代谢者风险最高。
要点
- CYP多态性可使慢代谢者的药物相互作用显著放大,最高约30倍。
- 红名单104个相互作用涉及13种底物和24种相互作用药物。
- 高敏感基因型为CYP2D6 *3-8/*3-8和CYP2C19 *2-3/*2-3。
核心结论
- CYP多态性可导致慢代谢者发生重大药物相互作用,而在快代谢者中可能不显著。
- 在所研究的104个相互作用中,最差情况下相互作用幅度可约大30倍。
- 药物相互作用的基因敏感性概念对精准医学发展有前景。
研究设计与样本
- 采用体内机制性静态模型预测药物相互作用的AUC比。
- 考虑5种CYP(CYP3A4/5、2D6、2C9、2C19、1A2)及3种多态CYP(CYP2D6、2C9、2C19)各5类基因型。
- 对196种底物和96种抑制剂的所有组合及所有基因型计算AUC比。
主要发现
- 获得104个敏感性大于3的相互作用红名单,涉及13种底物和24种相互作用药物。
- 高敏感59例,中敏感45例。
- 高敏感相关基因型为CYP2D6 *3-8/*3-8(敏感性达24.3)和CYP2C19 *2-3/*2-3(敏感性达37.8)。
关键数值与推荐
- AUC比大于5定义为最强相互作用。
- 中敏感:非快代谢者基因型组的相互作用比快代谢者强3至5倍。
- 高敏感:非快代谢者基因型组的相互作用比快代谢者强5倍以上。
临床怎么用
- 处方红名单中的药物组合时,应进行患者基因分型和/或底物治疗药物监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The magnitude of drug-drug interactions mediated by cytochrome P450 (CYP) may depend on the genotype of polymorphic cytochromes. The objective of this study was to identify drug-drug interactions with greater magnitude in CYP variant groups than in extensive metabolizers. METHODS: The in-vivo mechanistic static model was used to predict the area under the curve ratio of drug-drug interactions. Five cytochromes (CYP3A4/5, 2D6, 2C9, 2C19, 1A2) and five groups of genotypes for each polymorphic cytochrome (CYP2D6, 2C9, 2C19) were considered. The area under the curve ratios were calculated for all combinations and all genotypes for 196 substrates and 96 inhibitors. Among the strongest interactions (area under the curve ratio greater than 5), two levels of gene sensitivity of drug-drug interactions were defined: the intermediate sensitivity, with a three- to five-fold stronger interaction in genotype groups other than in extensive metabolizers, and the high sensitivity, with a more than five-fold stronger interaction than in genotype groups other than extensive metabolizers. RESULTS: A red list of 104 interactions with a sensitivity greater than 3, involving 13 substrates and 24 interactors was obtained. There were 59 and 45 cases of high and intermediate sensitivity, respectively. The genotypes associated with a high sensitivity were CYP2D6 *3-8 *3-8 (sensitivity up to 24.3) and CYP2C19 *2-3*2-3 (sensitivity up to 37.8). CONCLUSIONS: A cytochrome polymorphism may lead to major drug-drug interactions in poor metabolizers, while these interactions may not be significant in extensive metabolizers. Among the 104 cases studied, the interaction could be of ca. 30-fold larger magnitude in the worst case. Genotyping of the patient and/or therapeutic drug monitoring of the substrate should be carried out when an association mentioned in the red list is prescribed. The concept of gene sensitivity of drug-drug interactions appears promising for the development of precision medicine.
引用
- Fermier N, Bourguignon L, Goutelle S, et al. Identification of Cytochrome P450-Mediated Drug-Drug Interactions at Risk in Cases of Gene Polymorphisms by Using a Quantitative Prediction Model. Clin Pharmacokinet. 2018. PMID: 29572664. doi:10.1007/s40262-018-0651-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。